Greenberg Traurig, LLP’s Post

I hope this will be recorded. Sigh. Bummed to be a little too far away. But, if you're in the Boston area, go see Jeny Maier talk about the M&A landscape for Pharma and Biotech industries. Important learnings to be gained here, for sure. #digitalhealth #lifesciences cc: Phase2

Start the new year with fresh and relevant topics in an Athena Alliance peer group. It's a great way to meet other members and invest your time. I host the Sales & Marketing peer group, and we have a hot list of topics for Q1 and a deep well of cohosts. Join us on January 5th @ 9am PST! #executiveleadership #exeuctiveinsights #athenaalliance #salesandmarketing #CMO #salesexecutives

Dr. Jo Varshney: Winner of the 2024 Great Companies International Women Entrepreneur Award Name:  Dr. Jo Varshney Business Name: VeriSIM Life, Inc Location: San Francisco, USA Establishment (Year): 2017 Category: Health & Wellness Profession/ Specialty: Pharmaceuticals Jo Varshney With an average timeline of 13 years for drug discovery and development, millions of dollars and lives are lost due to failed drug candidates and diseases that go untreated. At VeriSIM Life, the mission is to mitigate these losses by eliminating inaccuracy and waste when translating drug candidates to clinical trials using leading-edge technology that predicts patient outcomes. https://lnkd.in/dypHqEm9

Last night, Mainstay Engineering Group's CEO, Laura Hughes, joined Verista, Inc.’s Broderick Jones, Spark Therapeutics, Inc.'s, Holly Brunbeck, MS and Thermo Fisher Scientific-Bioproduction's Nicholas Thompson Jr on the ISPE Delaware Valley Chapter (ISPE DVC) Women in Pharma Panel: Allyship and Advocacy in Driving Change and Shaping the Future of the Pharma Industry. The session, moderated by Verista's Leta Sledge highlighted the importance of allyship and advocacy in driving change and shaping the future of the #pharmaceuticalindustry. By promoting positive change, ethical practices, and collaboration within and across industries, we are ultimately contributing to the betterment of society – all part of our mission at Mainstay Engineering. Here’s a snapshot of why Allyship and Advocacy are so crucial: ·      Fosters Innovation & Collaboration between different industries & principles ·      Creates Shared Values & Ethical Practices ·      Impacts Public Health by supporting initiatives that address global health challenges ·      Contributes to Shaping Regulatory Compliance & Sustainability ·      Contributes to Diversity & Inclusion Advocacy and inclusive hiring practices ·      Creates Positive Stakeholder Relationships, and a network that fosters mutual growth and success ·      Creates Long-Term Business Viability of the pharmaceutical industry with responsible and ethical practices Special thanks to ISPE for including Mainstay, and to Holloway America and ZETA for sponsoring this event.  #MainstayEngineering #Pharmaceuticalengineering #lifesciences #allyship #advocacy

We recently attended #SLAS 2024! As a panelist for the "DEI in the Lab" discussion, Clarkston's Brandon Miller shared insights for #DEI in the #lifesciences industry. Here are 3 takeaways from that discussion: 1. DE+I initiatives should be prioritized throughout the fabric of your organization. 2. Be intentional and innovative to increase diverse representation and retention in clinical trials. 3. It’s imperative to design labs with accessibility in mind. Read more here: https://hubs.ly/Q02lQJTD0 And, learn more about Clarkston's DE+I consulting services here: https://hubs.ly/Q02lQDPs0

For a deep analysis of market trends that are impacting the life sciences industry, take a look at our attorneys’ analysis in the 2024 Chambers and Partners Global Practice Guide chapter on “Life Sciences U.S. Trends and Developments.” #lifesciences

Under the lead of Andreas Mayr and Florian Nikolai, DORDA advised Merz Group in the complex separation of its Aesthetics and Therapeutics divisions in Austria. 🩺💉 The transaction included the transfer of the Austrian Aesthetics division from the Austrian Merz Pharma Austria GmbH to a #ShelfCo by way of an asset deal. DORDA advised Merz Group on legal issues with a focus on life sciences and corporate law. The cooperation included the comprehensive support of the client throughout the entire transaction process. 🤝 Also advising on the transaction were: Francine Brogyanyi, Christoph Brogyányi, Florina Thenmayer, Katrin Repic, Stanislav Nekrasov, Isabel Maurer and Katja Ausweger #DORDA #Clarity #Transaction #MnA #AssetDeal 

Early-stage life sciences companies and the investors that back them are laser-focused on evidenced-based development and approval hurdles. However, even at early stages, failure to adequately prioritize more nuanced regulatory and compliance issues can have a significant impact on exit value and create potential liability for investors and acquirers. Geoffrey Levin, Torrey Cope, Marie Manley, Donielle McCutcheon, Andy Shoyer, Michele Tagliaferri, and Julea Lipiz highlight eight key areas for focus. Read more on "Key Regulatory and Compliance Considerations for Early-Stage Life Sciences Companies and Their Investors."

Check out our cross-disciplinary global life sciences thought piece addressing key considerations early-stage life sciences companies and their investors should keep top of mind #globallifesciences #sidleyaustin

How can life science companies foster a more inclusive industry? This #AAPIHeritageMonth we’re amplifying Asian American and Pacific Islander voices in the industry. In our May Member Spotlight, Frank Watanabe, CEO at Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), shares: “We are actually a fairly diverse industry at the ‘journeyman’ level … But as you rise up in an organization in our industry, that diversity drops off precipitously. By the time you get to the CEO … it tends to get homogenous at the top and that’s true at the board level, too. We have to take intelligent risks with people. If you insist on only hiring someone who has been a CEO or on a board before, that's a recipe for the perpetuation of what you've had in the past. Everyone who is a CEO today was a CEO for the first time once. For us to increase diversity at the top levels, we have to stretch people and be willing to take those kinds of chances, particularly with underrepresented groups.” Read more: https://bit.ly/3V4FOzV